Company news

Praxis Precision Medicines, Inc. news in 2024

Praxis Precision Medicines, Inc.'s news releases, calls and decks from 2024, newest first.

View company

Praxis Precision Medicines Announces Rare Pediatric Disease Designation Granted for Relutrigine in Dravet Syndrome

December 17, 2024

Praxis Precision Medicines to Present at Upcoming December Investor Conferences

December 2, 2024

Praxis Precision Medicines to Showcase Updates from Largest Epilepsy Pipeline of Precision Epilepsy Programs at the 2024 American Epilepsy Society Annual Meeting

November 25, 2024

Praxis Precision Medicines Provides Corporate Update and Reports Third Quarter 2024 Financial Results

November 5, 2024

Praxis Precision Medicines to Participate in Three Upcoming November Investor Conferences

November 5, 2024

Praxis Precision Medicines to Announce Third Quarter 2024 Financial Results and Host Conference Call on Wednesday, November 6, 2024

October 31, 2024

Praxis Precision Medicines presents on ulixacaltamide Essential3 program at the Movement Disorders Society 2024 International Congress

September 25, 2024

Praxis Precision Medicines to highlight their Epilepsy Portfolio at the International League Against Epilepsy 15th European Epilepsy Congress with six presentations

September 3, 2024

Praxis Precision Medicines announces positive topline results from the EMBOLD study in SCN2A and 8A developmental epilepsies, highlighting the disease-modifying potential of relutrigine

September 2, 2024

Praxis Precision Medicines to Announce Topline Data from the Phase 2 EMBOLD Study of Relutrigine (PRAX-562) in SCN2A and SCN8A Developmental and Epileptic Encephalopathies on September 3, 2024

September 1, 2024

Praxis Precision Medicines Provides Corporate Update and Reports Second Quarter 2024 Financial Results

August 12, 2024

Praxis Precision Medicines to Announce Second Quarter 2024 Financial Results and Host Conference Call on Tuesday, August 13, 2024

August 4, 2024

Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2024 Financial Results

May 12, 2024

Praxis Precision Medicines to Report First Quarter 2024 Financial Results on Monday, May 13, 2024

May 9, 2024

Praxis Precision Medicines to Present on Ulixacaltamide at the American Academy of Neurology 2024 Annual Meeting

April 11, 2024

Praxis Precision Medicines, Inc. Announces Pricing of $200 Million Public Offering

March 27, 2024

Praxis Precision Medicines Reports Positive Results of PRAX-628 Study Evaluating Photo Paroxysmal Response (PPR) Achieving 100% Response in Treated Patients

March 25, 2024

Praxis Precision Medicines to Host PRAX-628 Program Update

March 24, 2024

Praxis Precision Medicines Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial Results

March 4, 2024

Praxis Precision Medicines to Participate in TD Cowen’s 44th Annual Health Care Conference

February 29, 2024

Praxis Precision Medicines, Inc. Announces Pricing of $150.0 Million Public Offering

January 10, 2024

Praxis Precision Medicines Provides Update on Advancing Clinical Stage Portfolio

January 7, 2024

Praxis Precision Medicines Announces Licensing and Collaboration Agreement with Tenacia Biotechnology for Ulixacaltamide in Greater China

January 4, 2024

Calls in 2024

Decks in 2024